Premium
The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants
Author(s) -
Raz Michal Ariela,
Arnason Jon,
Bairey Osnat,
Shvidel Lev,
Aviv Ariel,
Ben Baruch Sharon,
Perry Chava,
Sarid Nadav,
Kirgner Ilya,
Dvid Varon,
Herishanu Yair,
Avivi Irit
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16422
Subject(s) - ibrutinib , medicine , rivaroxaban , mantle cell lymphoma , apixaban , dabigatran , retrospective cohort study , edoxaban , tolerability , adverse effect , warfarin , atrial fibrillation , gastroenterology , oncology , lymphoma , chronic lymphocytic leukemia , leukemia